

가

1

galectin - 3 , p53
(Fig. 1E, F). HBME - 1, CK - 19

1

가

가

38 가 5

2.9×5.5×7.6 cm

Jones (4) 1997
2,953

2003
249

1A, B)

(Fig.

13
(not published)

1

galectins

가

가

galectin - 3가

(5 - 7). Orlandi (6) galectin - 3

(Fig. 1C, D).

가

, Gasbarri (8) galectin - 3 CD44v6

(nuclear
grooves) (Fig. 1C, D)

galectin - 3
가

1
2

가

galectin - 3

2007 6 11

2007 10 15




Fig. 1. A, B. On axial and longitudinal scan of thyroid US, relatively defined hypoechoic portion within the thyroid nodule ($2.9 \times 5.5 \times 7.6$ cm) at the left lobe is observed (arrow), and this hypoechoic area was a target on US-guided fine-needle aspiration biopsy.

C, D. In the low power microscopic image, the nodule shows no fibrous capsule and distended follicles (long arrow) or solid area consisted of small sized follicles (short arrow), which is a typical configuration of nodular hyperplasia (C, H & E stain, $\times 15$). High power view of the solid area of the nodule reveals compact clusters of small follicles having enlarged ground glass nuclei, irregular nuclear margin and nuclear grooves (arrow), which are compatible findings of follicular variant of papillary thyroid carcinoma (D, H & E, $\times 200$).

E, F. The follicular cells of solid area within the nodule display focal positive reaction for galectin-3 (arrow), and positive nuclear reaction for p53 (Immunohistochemical stain, $\times 200$).

HBME - 1, CK - 19

가
가

가

low-up. *World J Surg* 1994;18:495-498

2. Chiarotti L, Berlingieri MT, De Rosa P, Battaglia C, Berger N, Bruni CB, et al. Increased expression of the negative growth factor, galactoside-binding protein gene, in transformed thyroid cells and in human thyroid carcinomas. *Oncogene* 1992;71:2507-2511
3. Naor D, Sionov RV, Ish-Shalom D. CD44: Structure, function, and association with the malignant process. *Adv Cancer Res* 1997;71:241-319
4. Jones C, Goujon JM, Gebelin H, Levillain P, Kraimps JL, Serpell JW. Malignant transformation of in benign thyroid nodules. The royal australasian college of surgeons annual scientific Congress, Perth 9-13 May 2005
5. Barondes SH, Castronovo V, Cooper DN, Cummings RD, Drickamer K, Feizi T, et al. Galectins: a family of animal beta-galactoside-binding lectins. *Cell* 1994;76:597-598
6. Orlandi F, Saggiorato E, Pivano G, Puligheddu B, Termine A, Cappia S, et al. Galectin-3 is a presurgical marker of human thyroid carcinomas. *Cancer Res* 1998;58:3015-3020
7. Finley DJ, Lubitz CC, Wei C, Zhu B, Fahey III TJ. Advancing the molecular diagnosis of thyroid nodules: defining benign lesions by molecular profiling. *Thyroid* 2005;15:562-568
8. Gasbarri A, Martegani MP, Del Prete F, Lucante T, Natali PG, Bartolazzi A. Galectin-3 and CD44v6 isoforms in the preoperative evaluation of thyroid nodules. *J Clin Oncol* 1999;17:3494-3502

1. Kuma K, Matsuzuka F, Yokozawa T, Miyauchi A, Sugawara M. Fate of untreated benign thyroid nodules: results of long-term fol-

J Korean Radiol Soc 2007;57:507 - 509

Malignant Transformation of Nodular Hyperplasia in the Thyroid: A Case Report¹

Hyun Sin In, M.D., Dong Wook Kim, M.D., Hye Kyoung Yoon, Ph.D²

¹Department of Radiology, Busan Paik Hospital, Inje University College of Medicine

²Department of Pathology, Busan Paik Hospital, Inje University College of Medicine

Thyroid carcinogenesis is traditionally thought to originate 'de novo'. However, it is debatable whether a malignant transformation can possibly arise from a benign thyroid nodule, as suggested for the malignant transformation of a thyroid adenoma. To the best of our knowledge, no studies have been performed addressing the malignant transformation of nodular hyperplasia in the thyroid gland. Here, we report a case of nodular hyperplasia with focally malignant degeneration.

Index words : Focal nodular hyperplasia
Cell transformation, neoplastic
Thyroid neoplasm
Thyroid, US

Address reprint requests to : Dong Wook Kim, M.D., Department of Radiology, Busan Paik Hospital, Inje University College of Medicine
633-165, Gaegeum-dong, Busanjin-gu, Busan 614-735, Korea
Tel. 82-51-890-6549 Fax. 82-51-896-1085 E-mail: dwultra@lycos.co.kr